Advertisement Sequenom terminates exchange offer to acquire Exact Sciences - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sequenom terminates exchange offer to acquire Exact Sciences

Sequenom, a developer of genetic analysis products, has terminated its exchange offer to acquire all of the outstanding shares of common stock of Exact Sciences, an applied genomics company, without accepting for exchange or exchanging any shares of Exact Sciences common stock.

Sequenom has previously announced that it would terminate the exchange offer if Exact Sciences entered into any out-licensing agreement, collaboration or financial restructuring. Sequenom continues to be committed to building its oncology diagnostic franchise.